Multiligand Nanoparticles for NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, particularly those targeting Natural Killer (NK) cells, face challenges such as on-target, off-tumor adverse events and limited activation due to poor expression of NK-activating ligands and overexpression of MHC I on cancer cells, hindering effective NK cell-mediated anticancer immunity.
Innovation Solution
Development of nanoparticles with a first targeting agent binding to NK cells and a second targeting agent binding to cancer cells, facilitating NK cell activation and cytotoxicity, and delivering therapeutic agents directly to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies targeting NK cells and tumor cells are used, then NK cell engagement and cytotoxicity are facilitated, but on-target, off-tumor adverse events occur
Solution Approach 1:
The patent divides the targeting function into two separate components: a first targeting agent on the nanoparticle that binds to NK cell surface targets, and a second targeting agent that binds to cancer cell surface targets. This segmentation allows independent optimization of each binding interaction and reduces off-tumor effects by requiring dual binding for full activation
Solution Approach 2:
The nanoparticle serves as an intermediary carrier that brings the first targeting agent (NK cell binder) and second targeting agent (cancer cell binder) into close proximity, facilitating simultaneous binding to both cell types and enabling controlled NK cell activation at the tumor site rather than systemic activation
2Reliability
If single NK activating ligand is used in bispecific antibodies, then NK cell activation is achieved, but NK activation is limited
Solution Approach 1:
The nanoparticle is designed to carry multiple different NK activating ligands (first targeting agent, second targeting agent, and optionally third targeting agent) on its surface, enabling it to activate NK cells through multiple different receptors and pathways simultaneously, thereby enhancing and diversifying NK cell activation potential
Solution Approach 2:
The patent creates a composite nanoparticle structure that integrates multiple types of targeting agents (antibodies, antibody fragments, or other binding molecules) with different specificities against NK cell surface targets, combining their functions into a single therapeutic agent that can engage multiple NK cell activation pathways
3Reliability
If poor expression of NK cell-activating ligands and overexpression of MHC I on cancer cells, then NK cell-mediated anticancer immunity is hampered, but tumor evasion mechanisms are established
Solution Approach 1:
The patent converts the tumor's overexpression of MHC I and co-inhibitory molecules, which normally protect against NK cell attack, into an opportunity by designing targeting agents that specifically recognize and bind to these abundant surface molecules, thereby using the tumor's own protective mechanisms as targets for enhanced NK cell engagement and cytotoxicity
Data Source
AI summary
The present invention provides methods and compositions comprising a particle comprising at least one first targeting agent which binds a first target on an NK cell surface, and at least one second targeting agent which binds a second target on a cancer cell surface, wherein the second targeting agent is different from the first targeting agent.